Anthony Brampton

Anthony Brampton has served on the Board of Directors since 2014. He has also served on the board of directors of the subsidiary, Origin Life Sciences Limited, a U.K. corporation, since 2015. After working initially as an analyst at leading investment banking firms in London, Mr. Brampton joined Cazenove & Co. in 1989 and became a corporate finance partner in 1999. Following the acquisition of Cazenove by J.P. Morgan, he assumed the role of Managing Director, corporate finance at J.P. Morgan Cazenove, where he had responsibility for healthcare and life sciences. Upon retiring from J.P. Morgan Cazenove in 2006, he has been actively involved in equity finance within the life sciences field. Mr. Brampton has held several non-executive directorships, including Abzena plc, a company providing chemistry services to biotechnology and pharmaceutical companies, Polar Capital Global Healthcare Trust, an investment fund, Domainex, a provider of preclinical drug discovery services, and iPulse Ltd., a consumer healthcare company. From 2014 to 2019, Mr. Brampton was also a partner at Longbow Capital, an investment advisor. He obtained both a B.A. and an M.Sc. in Biochemistry from the University of Oxford. The extensive financial and market knowledge of Mr. Brampton, combined with his experience as a director within the biotechnology industry, is believed to be instrumental in assisting the company in complying with the requirements of being a public company.